



George Panayotou, PhD

Researcher A'

Biomedical Sciences Research Center "Alexander Fleming"

E-mail panayotou@fleming.gr

Telephone 2109656310

Research Molecular Analysis of Signal Transduction Pathways

Keywords Signal transduction; Proteomics; Growth Factor Receptors; Kinases; Phosphatases; Cell growth; Cancer

Links PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=panayotou+g&sort=date>
Scholar: <https://scholar.google.com/citations?user=mJeG4hsAAAAJ&hl=en&authuser=1>
Webpage: <https://www.fleming.gr/research/ibi/researchers/panayotou-lab>

Biography

Cancer George Panayotou is currently Director and Chairman of the Board at the Biomedical Sciences Research Center "Alexander Fleming". He studied Chemistry at the University of Athens and Biochemistry at the University of Sussex and carried out his doctoral studies at the National Institute for Medical Research and University College London, funded by a scholarship from the Onassis Foundation. He obtained his PhD, entitled "Studies on the Epidermal Growth Factor Receptor", in 1987. He then joined Mike Waterfield's group at the Ludwig Institute for Cancer Research (University College London / Middlesex Hospital Branch), where he worked until 1998, while also being a honorary lecturer at UCL. In 1999 he was elected associate investigator at BSRC "Alexander Fleming". He served as director of the Institute of Molecular Oncology and as head of Fleming's Scientific Committee. His main research interests have included the structure and function of growth factor receptors, lipid and protein kinases and phosphatases, characterization of modular domains (SH2, SH3, PH) and proteomic approaches in cancer research, contributing more than 140 publications in scientific journals, which have attracted over 11,000 citations. He acts as a referee for various journals and grant awarding bodies and has been involved in extensive collaborations with pharmaceutical and biotech companies. His research group has been funded by competitive EU and national grants, and he is co-inventor in two awarded US patents.